Medication info
Janudaum MXR Sustained Release Tablets 100/1000 mg

Janudaum MXR Sustained Release Tablets 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Bright blue, bilaterally convex oval sustained-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201957 · Approved 2022.05.11 · Insurance code 694003910

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin treatment: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily, based on their current metformin dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes through the combined action of sitagliptin and metformin. It is primarily used to effectively manage blood sugar while complementing dietary and exercise regimens. Taking this medication can help maintain stable blood sugar levels, contributing to diabetes management. Patients are encouraged to use this medication along with consistent dietary control and exercise for better results. Therefore, this medication is used to improve blood sugar control in type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin treatment: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily, based on their current metformin dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin, which help regulate blood sugar levels. While taking this medication, it is important to note that although rare, serious allergic reactions may occur. If symptoms such as rash, hives, or difficulty breathing appear, discontinue use immediately and consult a doctor. Acute pancreatitis, which is inflammation of the pancreas, may occur; therefore, if symptoms like abdominal pain, vomiting, or nausea arise, careful observation is required, and healthcare professionals should be informed immediately. Patients with impaired kidney function should not use this medication, especially in cases of severe renal impairment or acute renal failure risk. Patients with a sudden decline in heart function or those suffering from acute heart failure should also avoid this medication for safety. Before and after tests involving iodinated contrast agents, this medication should be temporarily discontinued to reduce the risk of kidney damage and lactic acidosis. It is advisable for pregnant women or women who may become pregnant, as well as nursing mothers, to refrain from taking this medication. This medication can cause a rare but serious metabolic disorder known as lactic acidosis, so caution is required in conditions such as dehydration, severe infections, liver dysfunction, or excessive alcohol consumption. Additionally, there is a risk of hypoglycemia; thus, meals should be taken regularly, and when used in combination with other blood sugar-lowering agents, attention to hypoglycemia symptoms is critical. Regular monitoring of kidney function, blood tests, and vitamin B12 levels while on this medication is essential. If physical activity levels suddenly increase or meal patterns become irregular, caution is also advised, and the potential for drug interactions needs to be communicated to healthcare providers. In cases of surgery, severe infections, or trauma, this medication should be temporarily discontinued and resumed once the condition stabilizes. If severe joint pain or skin blistering occurs during this medication use, immediate consultation with a doctor is necessary. Lastly, when prescribing this medication to elderly patients, careful monitoring of kidney function and dosage adjustment is required.

Side effects

anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, blistering dermatitis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, severe arthralgia, blistering dermatitis, hypoglycemia, decreased vitamin B12, rash, urticaria, cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. Also, avoid places that are too hot or too cold, and it is important to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Bright blue, bilaterally convex oval sustained-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.